You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物科技服務(08037.HK):前海德潤資本管理擬向上海隆耀投資2000萬元

格隆匯1月26日丨中國生物科技服務(08037.HK)公吿,於2022年1月26日,公司一間間接非全資附屬公司上海隆耀生物科技有限公司與前海德潤資本管理(深圳)有限公司(投資者)訂立無法律約束力的條款清單,內容有關投資者擬向上海隆耀投資人民幣2000萬元。

若投資金額全部到位,投資者將持有交割完成後上海隆耀全部註冊資本總額的1.79%。投資金額將用於創新免疫細胞治療藥物的臨牀試驗、研發和GMP生產車間的建設等。

據悉,上海隆耀的業務為於中國提供腫瘤免疫細胞治療、免疫細胞存儲及健康管理服務。上海隆耀自主研發的一款CAR-T(嵌合抗原受體T細胞)產品LY007細胞注射液,於2021年1月20日取得中國國家藥監局的一期臨牀試驗許可,是中國第一款獲有關當局批准進入註冊臨牀以CD20為靶點的CAR-T產品。於2022年1月25日,上海隆耀於上海瑞金醫院順利召開了該LY007細胞注射液治療復發╱難治性CD20陽性B細胞非霍奇金淋巴瘤的耐受性、安全性和有效性的開放標籤、單臂I期臨牀研究中心啟動會。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account